A GLOBAL LEADER IN EPIGENETICS

INVESTOR PRESENTATION
MADX: ORY
OCTOBER 2019
This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon Genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation is not an offer of securities for sale in the United States. The Company’s securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company’s securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.
Company Highlights

- A clinical stage biopharmaceutical company developing innovative therapies in the field of Epigenetics
- Two molecules already with positive data in humans
- Large IP portfolio with technology fully developed in-house
- MADX: ORY A publicly traded company on the Spanish Stock Exchange
- Integrated in the IBEX Small Cap Index

- Raised an aggregate of circa €85M (in 2015-2019)
- Cash runway expected till 2H2021*
- One of the most LIQUID companies in the MicroCap group in the Spanish Stock Market
  - 45.7 M Shares outstanding. Fully diluted
  - 350,000 daily volume (Avg Traded Volume in 2018)
  - +88M shares negotiated in 2018 / ≈5 months for share full turnover

* On July 26th, the company completed a Private Placement with International Investors raising gross proceeds of €20M (circa $22.2M at the exchange rate on that day)

---

ORYZON GENOMICS SA
BALANCE SHEET DATA (UNAUDITED)¹
(Amounts in thousands US $)

<table>
<thead>
<tr>
<th></th>
<th>June 30th, 2019</th>
<th>June 30th, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>27,868</td>
<td>30,986</td>
</tr>
<tr>
<td>Marketable securities</td>
<td>669</td>
<td>165</td>
</tr>
<tr>
<td>Total Assets</td>
<td>73,125</td>
<td>68,352</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total Stockholders’ equity</td>
<td>50,888</td>
<td>40,697</td>
</tr>
</tbody>
</table>

¹ Spanish GAAPs
Epigenetic dysfunctions are associated with aberrant gene expression and disease

Epigenetic drugs can restore these transcriptional imbalances

Lysine specific histone demethylase 1 (LSD1), aka KDM1A, removes methyl marks at mono- and dimethyl-H3K4 (histone H3 lysine 4) and H3K9 (histone H3 lysine 9)

LSD1 is the most abundant histone demethylase in the prefrontal cortex

Figure from Arrowsmith et al. Nature Reviews Drug Discovery volume 11 (2012)
Oryzon is pioneering epigenetics in CNS and active in oncology

A broad pipeline to address unmeet medical needs with an attractive market opportunity

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>STUDY*</th>
<th>RESEARCH</th>
<th>PRECLINICAL</th>
<th>PHASE I</th>
<th>PHASE IIA</th>
<th>PHASE IIB</th>
<th>PHASE III</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAFIDEMSTAT (ORY-2001) - CNS optimized LSD1 inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aggression in BPD</td>
<td>REIMAGINE / PORTICO (***)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aggression in ADHD</td>
<td>REIMAGINE / ENTRANCE (***)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aggression in ASD</td>
<td>REIMAGINE / COLONNADE (***)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aggression in AD</td>
<td>REIMAGINE-AD / GATEWAY (***)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease (Mild Moderate)</td>
<td>ETHERAL monotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple Sclerosis (RR &amp; SP)</td>
<td>SATEEN monotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| IADADEMSTAT (ORY-1001) - selective LSD1 inhibitor | | | | | | | |
| AML (Elderly Unfit) | ALICE Combo w Aza | | | | | | |
| SCLC (First Line Relapsed) | CLEPSIDRA Combo w Platinum/Etoposide | | | | | | |

| ORY 3001 - selective LSD1 inhibitor | | | | | | | |
| Non Oncological | Preclinical finished | | | | | | |

| OTHER PROGRAMS | | | | | | | |
| Undisclosed | | | | | | | |

* IN BLUE, NEW PHASE III STUDIES UNDER PREPARATION OR EVALUATION
** Contingent to + results in REIMAGINE-AD

** CNS Market Need **

- Aggression is a common feature in many psychiatric diseases. +50% in ADHD(***)
- Global BPD market expected to grow to $2.6B in 2027
- 45 million people with AD worldwide; 20% shows aggressiveness
- AD main disruptions: memory loss, aggression and apathy. AD global costs per annum of $605B

** Oncology Market Need **

- Global AML market of $990m in 2019. Room for new Combos according to KoLs
- SCLC is a serious unmet medical need, with a MOS of 8–12 months and 5% 2-year OSR
- Global SCLC market +300,000 patients/y. FDA approved label extension of Pembro but only 19% of ORR (***)
- Projections of Rova-T when in Phase III were +5B peak sales/y

(****) Keynote study in 83 patients
VAFIDEMSTAT a Phase II Clinical Stage Compound with a broad developability in CNS diseases

- Vafidemstat is a **small molecule** LSD1 inhibitor optimized for CNS
- **Excellent Pharmacology.** High **oral** bioavailability
- **Positive** results in **7 different animal models** and in **in-vitro** models
  - Cognition
  - Neuroprotection
  - Neuroinflammation
  - Social Withdrawal / Apathy
  - Aggression / Agitation
  - Others
- Epigenetic **MoA** that modulates **neuroinflammation** and expression of key **plasticity neuronal genes**
- Biomarkers identified
- **Good Safety** in humans in Phase I+II trials with **+220 participants** so far
- **BBB penetrance** and (indirect) human brain target engagement established
- Pharmacologically active in humans

In Phase IIA in multiple clinical studies
Phase IIb studies under preparation
Vafidemstat, and LSD1 inhibition, improves cognition

**In Alzheimer’s SAMP8 model** vafidemstat restores memory by the NORT model

**In Huntington disease R6/1 model** vafidemstat improves memory by the NORT model

**In Schizophrenia SETD1a +/- model** iadademstat (ORY-1001) improves working memory

**In Psychosis & Schizophrenia** NMDA receptor-hypofunction mice model T-448 (TAKEDA) LSD1 inhibitor improves memory

Vafidemstat Fully Restores Memory Measured by NORT in SAMP8 AD Model

MILD

- Treatment from month 5 during 1 week
- Treated from month 6 during 1 month (Delayed start-1)

MODERATE

- Treatment from month 5 during 1 month, tested at month 7 (1 month after treatment cessation)

SEVERE

- Treatment from month 8 during 4 months (Delayed start-2)

Cognition and memory impairments are found in AD and dementias but also in Autism, Schizophrenia, Depression, Bipolar disorder and other psychiatric conditions
Vafidemstat Produces Significant Behavioural Changes

Vafidemstat Reduces Aggression in the Resident Intruder Test in the SAMP8 AD Mice model

Vafidemstat Enhances Sociability in the Three-Chamber Test in SAMP8 AD Mice

Vafidemstat Reduces Social Withdrawal in the Rat Isolation Model

TCT - Females 12M age
4 months treatment
Chamber Preference

Object Chamber
Mice Chamber

Number of evitations

0
100
200
300
400

Time (s)

SAMR1 - VEH
SAMP8 - VEH
SAMP8 ORY-2001 (0.96 mg/kg/day)

0
10
20
30
40

***

Veh Veh 0.16 0.48

ORY-2001
(mg/kg/day)

* * *

Control Isolated
MoA: an upstream epigenetic mechanism producing a dual activity, antinflammatory and prosynaptic

LSD1 localizes in vivo to enhancers and promoters of confirmed CNS disease risk genes
LSD1 binds to TFs that control IEG expression and stress in the PFC-amygdala axis, including SRF

- vafidemstat up-regulates genes associated with:
  - **Cognition**, notably memory and **executive functioning**
  - **Neuroplasticity**
- vafidemstat potentiates the response capacity of IEGs to stress
- vafidemstat reduces the expression of inflammatory genes including S100A9 and others

Vafidemstat potently down-regulated the expression of a subset of genes related to immune reaction and inflammation as S100A9 involved in OPC defective remyelination

Genes up-regulated in SAMP8 mice by vafidemstat included:
- **Baiap3**: involved in retrograde trafficking
- **Prph**: mutated in Amyotrophic Lateral Sclerosis (ALS),
- **Fabp7**: upregulation in drosophila favors long term memory consolidation
- **Doc2a**: activity-dependent modulator of excitatory synaptic transmission, relevant to memory formation
- **Kremen2 and Rspo1**, regulators of the WNT pathway

In vitro axon branching rescue assays ORY-1001 was 1000-fold more potent than TCP

Mukai et al 2019 [http://dx.doi.org/10.1101/529701](http://dx.doi.org/10.1101/529701)
Recapitulation and reversal of schizophrenia-related phenotypes in Setd1a-deficient mice
Vafidemstat: Safety demonstrated in a Phase I study

Safe and well tolerated in a +100 healthy volunteers (young and elderly) Phase I (MAD+SAD) study

- No hematological impact at planned doses
- Efficiently crossed the BBB (70-90%)
- Oral PK - Half Life of 22h allowing once daily oral
- PK/PD data allowed definition of recommended Phase II doses

Safe and well tolerated so far in diverse Phase II studies

- Vafidemstat has been already administered to +220 volunteers and patients
- Phase IIs (MS, AD, ADHD, BPD and ASD patients) with no safety signals to date
- Longest exposure to date: 15 months
Vafidemstat: REIMAGINE - a Basket trial in aggression

Duration
8 Weeks treatment + 4 weeks of follow up

Cohorts to be recruited

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Patients</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borderline Personality Disorder</td>
<td>6 patients</td>
<td>Done – Data reported in April 2019</td>
</tr>
<tr>
<td>Attention Deficit and Hyperactivity Disorder</td>
<td>6 patients</td>
<td>Done – Data reported in April 2019</td>
</tr>
<tr>
<td>Autism Spectrum Disorder</td>
<td>6 patients</td>
<td>Done – Data reported in Sept 2019</td>
</tr>
</tbody>
</table>

Endpoints

Safety

Efficacy:

Aggression / Agitation measured by CGI-S
Aggression / Agitation measured by CGI-I
Aggression / Agitation measured by NPI A/A 4 items
Psychiatric status measured by NPI Global assessment (12 items)
Change in specific disease scales
REIMAGINE the first proof of concept for vafidemstat in human patients

Patients of the three psychiatric indications: Borderline Personality Disorder (BPD) Attention Deficit and Hyperactivity Disorder (ADHD) and Autistic Spectrum Disorder (ASD) Treated With Vafidemstat Showed a Reduced Aggressivity

Secondary Endpoints: Efficacy

Significant improvements in aggression evaluated using the Neuropsychiatric Inventory 4-item agitation/aggression score (NPI-A/A)

NPI-A/A Agitation/Aggression (4 items)

- BPD
- ADHD
- ASD
- All Patients

Also significant improvements in aggression evaluated using the Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I) scales

Data presented at CINP 2019
REIMAGINE the first proof of concept for vafidemstat in human patients

The significant improvements in the NPI global score and overall specific scales for BPD and ADHD suggest that vafidemstat has a broader psychiatric effect beyond aggression.

Data presented at CINP 2019

Remarkably, vafidemstat not only improved aggression but also produced significant improvement on the GLOBAL Borderline Personality Disease Checklist (BPDCL) scale.
Next steps: Vafidemstat, a meaningful therapeutic option for BPD

"I find myself able now to control my negative emotions and my frustration"
Patient with severe borderline personality disorder during treatment with vafidemstat. Testimony to her psychiatrist Dr. Marc Ferrer

The company recognizes a significant development potential for vafidemstat in psychiatric indications

- Vafidemstat may be a disease modifying therapeutic option for BPD: reduces aggression and produces an overall improvement of the core features of the disease, with no sedation and no weight gain
- BPD prevalence ranges between 0.5%-1.4% of the total population (≤ 9.1M in US+EU5)
- The treatment of BPD is now based on psychotherapeutic interventions. No drugs currently approved for this condition
- A significant unmet medical need
- Global BPD Market, 2018-2027 (US$), $2.6B expected in 2027

- A new Phase IIb in BPD (Portico) under preparation
- Additional Phase IIb in adult aggressive ADHD (Entrance) and ASD (Colonnade) under evaluation
- And if +data in Reimagine-AD, a Phase IIb in AD aggressive patients (Gateway) will be performed
Vafidemstat: a new therapeutic option for aggression in Alzheimer’s disease

REIMAGINE - AD: A Phase IIa trial in Moderate and Severe AD

<table>
<thead>
<tr>
<th>Duration</th>
<th>24 Weeks treatment + 4 weeks of follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open Label / Single arm (1.2mg/d)</td>
<td>12 patients</td>
</tr>
<tr>
<td>Recruitment Finished</td>
<td>(Data report expected in April 2020)</td>
</tr>
</tbody>
</table>

- Safety
- Efficacy: Aggression / Agitation measured by NPI A/A 4 items, CMAI and CGI-A/A
- Memory status measured by MMSE
- Caregiver burden measured by changes in the Zarit Burden Interview (ZBI)

First proposition in AD: Vafidemstat as a symptomatic drug

- 45 million people affected worldwide
- 20% of the outpatients and 40% of the inmate patients display aggressiveness
- Vafidemstat is safe and highly brain-penetrant in humans
- Positive effects in different preclinical models on memory, aggression, sociability and apathy, all core features in AD patients
- Vafidemstat reduces aggression in BPD, ADHD and ASD patients

Vafidemstat may also provide clinical benefit in AD either as a single or multi-symptomatic drug or as a disease modifier
An ambitious Phase II trial, ETHERAL: Epigenetic THERapy in ALzheimer’s Disease

Besides aggression, vafidemstat may provide also further benefits to AD patients

Phase IIa study to provide useful information to design future Phase II/III studies

- 150 Mild to Moderate AD patients (6+6 months)
- Primary Objective: Safety & Tolerability
- Secondary Objectives:
  - Cognition/Agitation/Apathy/Depression/QoL
  - Volumetric MRI
- Biomarker guided study (with 8 CSF Biomarkers)

- 117 patients in EU. 17 sites
- Spain, France & UK

- A Twin study in US: around 25-28 patients
- IND approved mid March
- US Sites (3) opened
- FPI recruited in May

Besides aggression, vafidemstat may provide also further benefits to AD patients. Phase IIa study to provide useful information to design future Phase II/III studies.

- 150 Mild to Moderate AD patients (6+6 months)
- Primary Objective: Safety & Tolerability
- Secondary Objectives:
  - Cognition/Agitation/Apathy/Depression/QoL
  - Volumetric MRI
- Biomarker guided study (with 8 CSF Biomarkers)

- 117 patients in EU. 17 sites
- Spain, France & UK

- A Twin study in US: around 25-28 patients
- IND approved mid March
- US Sites (3) opened
- FPI recruited in May

Aside from aggression, vafidemstat may also provide further benefits to AD patients. Phase IIa study to provide useful information to design future Phase II/III studies.

- 150 Mild to Moderate AD patients (6+6 months)
- Primary Objective: Safety & Tolerability
- Secondary Objectives:
  - Cognition/Agitation/Apathy/Depression/QoL
  - Volumetric MRI
- Biomarker guided study (with 8 CSF Biomarkers)

- 117 patients in EU. 17 sites
- Spain, France & UK

- A Twin study in US: around 25-28 patients
- IND approved mid March
- US Sites (3) opened
- FPI recruited in May
Vafidemstat appears to be safe in AD patients: ETHERAL first data report

One of the main goals in ETHERAL is to establish safety of vafidemstat in long-term administration, at therapeutically relevant doses in a frail and elder AD population

Vafidemstat treatment appears so far to be safe and well tolerated:

- Four SAEs were reported in three subjects, all suspected to be unlikely related to the treatment
- Platelet, neutrophils and other hematological parameters do not show clinically relevant variations due to vafidemstat treatment
- No abnormal and clinically significant liver enzymes levels or other laboratory findings have been reported to-date

Biomarker and other functional evolution in ETHERAL (blind analysis) is compatible with an informative study

Variations on the S100A9 CSF levels observed in the first 33 patients completing the first 24 weeks of therapy (blind analysis) might be compatible with the preclinical data that shows that vafidemstat decreases S100A9 levels in the CNS. S100A9 is a proinflammatory protein reported to be highly overexpressed in PFC in AD patients

![Graph showing S100A9 Change from Baseline (CFB) with fold induction after 24 weeks treatment. The graph includes data for both moderate and mild categories.]
Iademstat

A Phase II stage clinical compound in Oncology
Iadademstat (ORY-1001): the most advanced selective LSD1 inhibitor in clinic

- LSD1 is involved in different cancers. **High levels of LSD1 often correlate with more aggressive forms of cancer and/or bad prognosis**

- Iadademstat is a small molecule that selectively inhibits LSD1. Preclinical positive *in vivo* results in different xenograft models. Best in Class. Full characterization published in top-rank journal.

- First LSD1i drug to enter into clinical trials. Encouraging results in a FiM Acute Leukemia Phase I/IIa trial

---

**Phase I/IIa acute leukemia - previous data**

- Safe and very well tolerated and therefore a meaningful candidate for combination with other agents

- PD Biomarkers identified in different subsets of leukemia

- Antileukemic activity observed in 29% of patients (12/41), including one CRi as Proof of Biological concept
Iadademstat a flexible CDP for a Large Market Opportunity

POTENTIAL ONCOLOGICAL INDICATIONS:

**Solid Tumors**
- Small Cell Lung Cancer
- Prostate cancer
- Colorectal cancer
- Bladder cancer
- Some breast cancers
- Merkel Cell Carcinoma

**HemONC**
- AML
- MDS
- Myelofibrosis
- Non Hodgkin Lymphoma

**Brain/rare Tumors**
- Medulloblastoma
- Glioblastoma

MoA well characterized in SCLC, AML and Medulloblastoma
Iadademstat in AML: Phase II Study - First signs of efficacy

**ALICE: An AML trial with LSD1i in Combination with azacitidine in the Elderly**

A Phase IIa study to evaluate the safety, tolerability, dose finding and efficacy of iadademstat (ORY-1001) in combination with azacitidine in older patients with AML in first line therapy

- Single arm & Open label. Up to 36 patients to be enrolled
- **Primary endpoint:** Safety and tolerability of the combo with hypomethylating agent azacitidine
- **Secondary endpoints:** Responses; time to responses; duration of response; and overall survival

**Preliminary Results**

(5 evaluable patients out of 6)

- Combo well tolerated
- Fast responses (median time to response 1.5 months)
- **80% OR** (4/5 evaluable patients): 75% CRi and 25% PR
- 1 patient in CRi with decreasing need of transfusions
- Additional reports to be presented in future Medical Conferences
Iadademstat opportunity in Small Cell Lung Cancer (SCLC)

- LSD1 is a target well characterized in SCLC and validated in preclinical models. LSD1 inhibitors are effective in several in-vitro and in-vivo models of SCLC.
- Iadademstat produces complete and durable tumor regression in different chemoresistant PDX models.
- Characterized MoA.
- Identified and patented Biomarkers that are differential in sensitive SCLC cell lines, tumors and plasma from patients.
- Phase II trial ongoing in second line SCLC patients using these biomarkers to stratify patients and identify super-responders.
CLEPSIDRA: A Combination trial of LSD1 and Etop-Platinum in Small Cell Lung Cancer in biomarker-ID Relapsed pAitients

A Phase Ila study to assess the safety, tolerability, dose finding and efficacy of iademstat (ORY-1001) in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer who are positive to candidate predictive biomarkers

- Single arm
- Open label; 4 sites in Spain
- Up to 36 patients to be enrolled
- 4-6 cycles iademstat+platinum/etoposide, thereafter iademstat monotherapy (at investigators’ criteria)
- **Primary end point:** Safety and tolerability of the combo with platinum-etoposide therapy
- **Secondary endpoints:** RECIST responses; time to responses; duration of response; and overall survival

Current status:

- 10 Patients enrolled. One patient at cycle 13
iadademstat: SCLC - Phase II CLEPSIDRA - preliminary efficacy signals

- **Main toxicity observed in the combination with carboplatin-etoposide is hematotoxicity**
- **75% response rate** (6/8 evaluable patients): 4PRs and 2 long-term SD
- Current level of observed responses suggests that **patient selection by Biomarkers** may be effective to increase ratio of ORs
- **iadademstat alone is safe and shows no hematological, general or neuronal toxicity** in ED-SCLC patients, suggesting potential for monotherapy and other combos
- Patient #1 showed initially 78.7% of tumor reduction after 6 cycles of triplet. Since then, and on iadademstat alone, patient is still in remission after 9 months (cycle 12) with 86.3% of tumor reduction by RECIST values and with all minor lesions still progressively being reduced or disappearing according to the 3 CT-Scans done since C6
Anticipating a rich flow of catalysts / clinical data

**ladademstat Phase IIs in oncology**

- **CLEPSIDRA**
- **ALICE**

**2019**

- **CLEPSIDRA**
- **ALICE**

- **Barcelona; Sept. SCLC data**
- **Orlando; Dec. AML data**

**2020**

- **Chicago; June SCLC & AML data**
- **July; Amsterdam AD Global US 6m data**

**Vafidemstat Phase IIs in CNS**

- **REIMAGINE**
- **ETHERAL**
- **SATEEN**

- **April; Warsaw BPD Aggression**
- **Sept.; Copenhagen ASD Aggression**
- **Oct.; Athens Psychiatry Aggression**
- **April; Lisbon ADHD Aggression**
- **AD aggression**
- **AD Global EU 6m data**
- **AAML data**
ORYZON – a unique investment opportunity in an epigenetic platform

- A differential proposition in **EPGENETICS** drugs in **CNS and ONCOLOGY** around one of the most interesting targets in the field: **LSD1**
- **2 molecules** in **Phase II** with promising clinical signals in human patients
- **Pioneers in CNS epigenetics**
  - Vafidemstat shows efficacy in psychiatric disorders (BPD, ADHD, ASD)
  - **Phase IIb in Borderline personality disorder under preparation.** Additional options in ADHD or ASD under evaluation
  - Vafidemstat may be also clinically relevant in neurodegenerative disorders (Phase IIs in MS and AD ongoing)
- **Most advanced LSD1i (iadademstat) in Oncology**
  - 2 Phase II trials ongoing in combo with respective SoC in AML and SCLC
  - **Positive preliminary efficacy results** reported from Phase II AML and SCLC trials
  - **SCLC trial is a biomarker-guided** study to stratify responsive patients
  - Options to get accelerated approval
- **Rich pipeline** of clinical **news** expected in the next 2-4 Qs
- Clinical Operations in US started and under expansion
- A **cash efficient** company with a seasoned international management team
- **€135M market cap.** One of the most liquid stocks in the microcap group in MadridSEXC
- Perseverant **presence in the US market in the last 4 years.** Two successful PIPEs executed in 2018-19 led by US Investment Banks and with participation of US investors
- A public company in Europe with **plans to get dual listed in NASDAQ**
EXPERIENCED MANAGEMENT TEAM

CARLOS BUESA: CEO & President. Spain/US
PhD in Biochemistry and Molecular Biology.
Founder and CEO since inception.
Advanced programs on finance, business
development, negotiation skills and human resources.
He is also PADE at the IESE Business School.
Board Member of the VC Fund Inveready and
VicePresident of the Spanish BioIndustry Association.

MICHAEL T. ROPACKI: US
Vice President of Clinical Development
PhD in Clinical Neuropsychology.
Dr. Ropacki has held roles of increasing responsibility for +10y
at Johnson & Johnson, his last as
Director of Clinical Development, Neuroscience, Research and
Development, for Janssen R&D
serving as the Clinical Lead responsible for
developing and leading the
CNS in Lundbeck involved in +40 Clinical Trials in CNS.
Experience in oncology and
other indications in Regeneron
and other companies.

SONIA GUTIERREZ: Spain
Chief of Clinical Operations
BSc. Pharm. & MSc. & PDD in
ISEE Business School.
More than 20 years of experience in the clinical
research and operations area at
different International Pharma & Biotech companies.
CNS: +13y in Lundbeck involved in +40 Clinical Trials in CNS.
Experience in oncology and
other indications in Regeneron
and other companies.

NEUS VIRGILI: Spain
Chief IP Officer
B.Sc. in Organic Chemistry from
the University of Barcelona.
Qualified European Patent
Attorney.
Over 20 years experience in
pharmaceutical IP.
Since 2011 IP Officer at Oryzon.

EMILI TORRELL: Spain
Chief BD Officer
B.Sc. in Sciences, Autonomous
University of Barcelona.
MBA at ESADE and PDG at
ISEE Business School.
In the business development
area from 1990 in the most
relevant Spanish companies
Prodesfarma, Almirall and
Laboratorios Esteve.
From 2007 BD Director at
Oryzon.

TAMARA MAES: CSO & VicePresident. Spain
PhD in Biotechnology.
Founder and Chief Scientific Officer since inception.
Responsible of the creation of the whole pipeline of
the company and the biological target validation
programs.
SAB member on several public institutions as CSIC
(2009-2013) and private companies. Since 2016
Scientific Advisor of the ADDF.

RONALD LAM: US
Vice President of Medical Affairs
PhD in Biotechnology.
Qualified European Patent
Attorney.
Over 20 years experience in
pharmaceutical IP.

CARLOS BUESA: CEO & President. Spain/US
PhD in Biochemistry and Molecular Biology.
Founder and CEO since inception.
Advanced programs on finance, business
development, negotiation skills and human resources.
He is also PADE at the IESE Business School.
Board Member of the VC Fund Inveready and
VicePresident of the Spanish BioIndustry Association.

EXPERIENCED MANAGEMENT TEAM

An experienced and respected managerial team in the Biopharmaceutical industry
Team members have a track record in product discovery & in advancing successfully through product development phases
Demonstrated ability to close world class deals and to lead, and participate in international consortia
ORYZON
A GLOBAL LEADER IN EPIGENETICS

CARLOS BUESA
CEO & President
cbuesa@oryzon.com

ROGER BULLOCK
Chief Medical Officer
rbullock@oryzon.com

TAMARA MAES
Chief Scientific Officer
tmaes@oryzon.com

MICHAEL ROPACKI
VP Clinical Development
mropacki@oryzon.com